Phenotypic evaluation and in silico ADMET properties of novel arylimidamides in acute mouse models of Trypanosoma cruzi infection

Cristiane França da Silva, Denise da Gama Jaén Batista, Julianna Siciliano de Araújo, Edézio Ferreira Cunha-Junior, Chad E. Stephens, Moloy Banerjee, Abdelbasset A. Farahat, Senol Akay, Mary K. Fisher, David W. Boykin, Maria de Nazaré Correia Soeiro

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Arylimidamides (AIAs), previously termed as reversed amidines, present a broad spectrum of activity against intracellular microorganisms. In the present study, three novel AIAs were evaluated in a mouse model of Trypanosoma cruzi infection, which is the causative agent of Chagas disease. The bis-AIAs DB1957, DB1959 and DB1890 were chosen based on a previous screening of their scaffolds that revealed a very promising trypanocidal effect at nanomolar range against both the bloodstream trypomastigotes (BTs) and the intracellular forms of the parasite. This study focused on both mesylate salts DB1957 and DB1959 besides the hydrochloride salt DB1890. Our current data validate the high activity of these bis-AIA scaffolds that exhibited EC50 (drug concentration that reduces 50% of the number of the treated parasites) values ranging from 14 to 78 nM and 190 to 1,090 nM against bloodstream and intracellular forms, respectively, also presenting reasonable selectivity indexes and no mutagenicity profile predicted by in silico absorption, distribution, metabolism, excretion, and toxicity (ADMET). Acute toxicity studies using murine models revealed that these AIAs presented only mild toxic effects such as reversible abdominal contractions and ruffled fur. Efficacy assays performed with Swiss mice infected with the Y strain revealed that the administration of DB1957 for 5 consecutive days, with the first dose given at parasitemia onset, reduced the number of BTs at the peak, ranging between 21 and 31% of decrease. DB1957 was able to provide 100% of animal survival, while untreated animals showed 70% of mortality rates. DB1959 and DB1890B did not reduce circulating parasitism but yielded >80% of survival rates.

Original languageEnglish (US)
Pages (from-to)1095-1105
Number of pages11
JournalDrug Design, Development and Therapy
Volume11
DOIs
StatePublished - Apr 3 2017

Fingerprint

Trypanosoma cruzi
Computer Simulation
Parasites
Salts
Amidines
Mesylates
Parasitemia
Chagas Disease
Poisons
Infection
Survival Rate
Mortality
Pharmaceutical Preparations

Keywords

  • Arylimidamides
  • Chagas disease
  • Experimental chemotherapy
  • In vivo assays

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Phenotypic evaluation and in silico ADMET properties of novel arylimidamides in acute mouse models of Trypanosoma cruzi infection. / da Silva, Cristiane França; Batista, Denise da Gama Jaén; de Araújo, Julianna Siciliano; Cunha-Junior, Edézio Ferreira; Stephens, Chad E.; Banerjee, Moloy; Farahat, Abdelbasset A.; Akay, Senol; Fisher, Mary K.; Boykin, David W.; Soeiro, Maria de Nazaré Correia.

In: Drug Design, Development and Therapy, Vol. 11, 03.04.2017, p. 1095-1105.

Research output: Contribution to journalArticle

da Silva, CF, Batista, DDGJ, de Araújo, JS, Cunha-Junior, EF, Stephens, CE, Banerjee, M, Farahat, AA, Akay, S, Fisher, MK, Boykin, DW & Soeiro, MDNC 2017, 'Phenotypic evaluation and in silico ADMET properties of novel arylimidamides in acute mouse models of Trypanosoma cruzi infection', Drug Design, Development and Therapy, vol. 11, pp. 1095-1105. https://doi.org/10.2147/DDDT.S120618
da Silva, Cristiane França ; Batista, Denise da Gama Jaén ; de Araújo, Julianna Siciliano ; Cunha-Junior, Edézio Ferreira ; Stephens, Chad E. ; Banerjee, Moloy ; Farahat, Abdelbasset A. ; Akay, Senol ; Fisher, Mary K. ; Boykin, David W. ; Soeiro, Maria de Nazaré Correia. / Phenotypic evaluation and in silico ADMET properties of novel arylimidamides in acute mouse models of Trypanosoma cruzi infection. In: Drug Design, Development and Therapy. 2017 ; Vol. 11. pp. 1095-1105.
@article{198a97f4414c4dcb86707428610f5be7,
title = "Phenotypic evaluation and in silico ADMET properties of novel arylimidamides in acute mouse models of Trypanosoma cruzi infection",
abstract = "Arylimidamides (AIAs), previously termed as reversed amidines, present a broad spectrum of activity against intracellular microorganisms. In the present study, three novel AIAs were evaluated in a mouse model of Trypanosoma cruzi infection, which is the causative agent of Chagas disease. The bis-AIAs DB1957, DB1959 and DB1890 were chosen based on a previous screening of their scaffolds that revealed a very promising trypanocidal effect at nanomolar range against both the bloodstream trypomastigotes (BTs) and the intracellular forms of the parasite. This study focused on both mesylate salts DB1957 and DB1959 besides the hydrochloride salt DB1890. Our current data validate the high activity of these bis-AIA scaffolds that exhibited EC50 (drug concentration that reduces 50{\%} of the number of the treated parasites) values ranging from 14 to 78 nM and 190 to 1,090 nM against bloodstream and intracellular forms, respectively, also presenting reasonable selectivity indexes and no mutagenicity profile predicted by in silico absorption, distribution, metabolism, excretion, and toxicity (ADMET). Acute toxicity studies using murine models revealed that these AIAs presented only mild toxic effects such as reversible abdominal contractions and ruffled fur. Efficacy assays performed with Swiss mice infected with the Y strain revealed that the administration of DB1957 for 5 consecutive days, with the first dose given at parasitemia onset, reduced the number of BTs at the peak, ranging between 21 and 31{\%} of decrease. DB1957 was able to provide 100{\%} of animal survival, while untreated animals showed 70{\%} of mortality rates. DB1959 and DB1890B did not reduce circulating parasitism but yielded >80{\%} of survival rates.",
keywords = "Arylimidamides, Chagas disease, Experimental chemotherapy, In vivo assays",
author = "{da Silva}, {Cristiane Fran{\cc}a} and Batista, {Denise da Gama Ja{\'e}n} and {de Ara{\'u}jo}, {Julianna Siciliano} and Cunha-Junior, {Ed{\'e}zio Ferreira} and Stephens, {Chad E.} and Moloy Banerjee and Farahat, {Abdelbasset A.} and Senol Akay and Fisher, {Mary K.} and Boykin, {David W.} and Soeiro, {Maria de Nazar{\'e} Correia}",
year = "2017",
month = "4",
day = "3",
doi = "10.2147/DDDT.S120618",
language = "English (US)",
volume = "11",
pages = "1095--1105",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Phenotypic evaluation and in silico ADMET properties of novel arylimidamides in acute mouse models of Trypanosoma cruzi infection

AU - da Silva, Cristiane França

AU - Batista, Denise da Gama Jaén

AU - de Araújo, Julianna Siciliano

AU - Cunha-Junior, Edézio Ferreira

AU - Stephens, Chad E.

AU - Banerjee, Moloy

AU - Farahat, Abdelbasset A.

AU - Akay, Senol

AU - Fisher, Mary K.

AU - Boykin, David W.

AU - Soeiro, Maria de Nazaré Correia

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Arylimidamides (AIAs), previously termed as reversed amidines, present a broad spectrum of activity against intracellular microorganisms. In the present study, three novel AIAs were evaluated in a mouse model of Trypanosoma cruzi infection, which is the causative agent of Chagas disease. The bis-AIAs DB1957, DB1959 and DB1890 were chosen based on a previous screening of their scaffolds that revealed a very promising trypanocidal effect at nanomolar range against both the bloodstream trypomastigotes (BTs) and the intracellular forms of the parasite. This study focused on both mesylate salts DB1957 and DB1959 besides the hydrochloride salt DB1890. Our current data validate the high activity of these bis-AIA scaffolds that exhibited EC50 (drug concentration that reduces 50% of the number of the treated parasites) values ranging from 14 to 78 nM and 190 to 1,090 nM against bloodstream and intracellular forms, respectively, also presenting reasonable selectivity indexes and no mutagenicity profile predicted by in silico absorption, distribution, metabolism, excretion, and toxicity (ADMET). Acute toxicity studies using murine models revealed that these AIAs presented only mild toxic effects such as reversible abdominal contractions and ruffled fur. Efficacy assays performed with Swiss mice infected with the Y strain revealed that the administration of DB1957 for 5 consecutive days, with the first dose given at parasitemia onset, reduced the number of BTs at the peak, ranging between 21 and 31% of decrease. DB1957 was able to provide 100% of animal survival, while untreated animals showed 70% of mortality rates. DB1959 and DB1890B did not reduce circulating parasitism but yielded >80% of survival rates.

AB - Arylimidamides (AIAs), previously termed as reversed amidines, present a broad spectrum of activity against intracellular microorganisms. In the present study, three novel AIAs were evaluated in a mouse model of Trypanosoma cruzi infection, which is the causative agent of Chagas disease. The bis-AIAs DB1957, DB1959 and DB1890 were chosen based on a previous screening of their scaffolds that revealed a very promising trypanocidal effect at nanomolar range against both the bloodstream trypomastigotes (BTs) and the intracellular forms of the parasite. This study focused on both mesylate salts DB1957 and DB1959 besides the hydrochloride salt DB1890. Our current data validate the high activity of these bis-AIA scaffolds that exhibited EC50 (drug concentration that reduces 50% of the number of the treated parasites) values ranging from 14 to 78 nM and 190 to 1,090 nM against bloodstream and intracellular forms, respectively, also presenting reasonable selectivity indexes and no mutagenicity profile predicted by in silico absorption, distribution, metabolism, excretion, and toxicity (ADMET). Acute toxicity studies using murine models revealed that these AIAs presented only mild toxic effects such as reversible abdominal contractions and ruffled fur. Efficacy assays performed with Swiss mice infected with the Y strain revealed that the administration of DB1957 for 5 consecutive days, with the first dose given at parasitemia onset, reduced the number of BTs at the peak, ranging between 21 and 31% of decrease. DB1957 was able to provide 100% of animal survival, while untreated animals showed 70% of mortality rates. DB1959 and DB1890B did not reduce circulating parasitism but yielded >80% of survival rates.

KW - Arylimidamides

KW - Chagas disease

KW - Experimental chemotherapy

KW - In vivo assays

UR - http://www.scopus.com/inward/record.url?scp=85017210271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017210271&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S120618

DO - 10.2147/DDDT.S120618

M3 - Article

C2 - 28435221

AN - SCOPUS:85017210271

VL - 11

SP - 1095

EP - 1105

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -